EW
Healthcare · Medical Devices
Performance
EW (EW) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
EW (EW) operates in the Medical Devices space within the Healthcare sector. With a market cap of $51.4B, it qualifies as a mid-cap company. The company is growing revenue strongly while maintaining healthy profitability — a combination that investors typically reward with a premium valuation.
- Forward P/E (26.5×) is lower than trailing P/E (48.3×) — analysts expect earnings to improve
- Revenue growth of 17% YoY shows solid business momentum
- Healthy profit margin of 17.4%
- Current ratio of 4.4× — ample short-term liquidity
- High P/E of 48.3× implies high expectations already priced in — leaves little room for disappointment
- High debt-to-equity of 6.81× increases financial risk, especially with elevated interest rates
- No dividend history — total return depends entirely on price appreciation
- Price is near its 52-week high — limited near-term upside, higher pullback risk
Verdict
Hold
Mixed signals — strengths and risks roughly balance. Wait for a clearer catalyst.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
This stock does not pay dividends.
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Jul 23, 2026
37
days
EPS (TTM)
$1.85
P/E (TTM)
48.3
Fwd P/E
26.5
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $89.34
Graham Number
√(22.5 × EPS × Book Value)
$27.30
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
N/A
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
75% score
Pays dividends
No dividend history found
Dividend consistency (5Y+)
Uninterrupted dividend payments for at least 5 years
ROE above 10%
10.5%Return on equity — measures how efficiently capital is used
Positive profit margin
17.4%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+16.7%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+8.2%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
6.81×Low financial leverage reduces risk of distress
Current ratio above 1
4.42×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$448M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
Healthcare
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.